Logo

U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season - Merck.com

Last Updated: 28.06.2025 14:45

U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season - Merck.com

June 9, 2025 3:11 pm ET

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has ap… [+11553 chars]

RAHWAY, N.J.--(BUSINESS WIRE)--

What do you think of Hegseth calling The Atlantic journalist Jeffrey Goldberg, "a deceitful and highly discredited so-called journalist who has made a profession of peddling hoaxes” after team Trump texted him their top-secret war plans on Yemen?